On March 27, 2026, Teleflex Incorporated (NYSE: TFX) received an “Outperform” rating from Jayson Bedford at Raymond James. This endorsement comes as the company, currently trading at $116.22, faces significant volatility yet boasts a price target of $128, suggesting notable upside potential for investors.
Recent Price Action
In recent trading sessions, TFX has shown signs of resilience amidst market turbulence, closing at $116.22 with a notable increase of 5.73 points, representing a 5.19% uptick. This comes against a backdrop of a year marked by a 52-week low of $18.94 and a high of $33.36, emphasizing the stock’s considerable fluctuations. Trading volume also surged to 1,089,669 shares, well above its average of 941,022, indicating heightened investor interest. With a market capitalization of approximately $5.14 billion and a beta of 0.861, TFX exhibits lower volatility relative to the broader market, which may appeal to risk-averse investors seeking opportunities in a choppy trading environment.
Historical Performance
Despite the recent uptick in price, Teleflex’s performance over the past year reveals substantial challenges. The stock has declined by 44.7% over the last twelve months, reflecting broader market conditions and company-specific issues. More granularly, TFX’s performance over the past 30 days shows a decrease of 19.79%, with a quarterly decline of 21.69%. Weekly volatility has hovered around 2.9%, while monthly volatility stands at 2.87%. These metrics suggest that while the stock is currently rallying, its historical performance paints a less optimistic picture, warranting caution for potential investors.
Earnings Analysis
The latest earnings report, released on November 6, 2025, revealed a stark contrast between actual and estimated earnings per share (EPS). Teleflex reported an actual EPS of -$9.24 against an estimate of $3.38, marking a staggering earnings surprise of -373.47%. This significant deviation from expectations raises concerns about the company’s earnings quality and predictability, particularly when compared to the prior quarter, where TFX exceeded estimates with an EPS of $3.73 against an expectation of $3.36. The substantial earnings miss could contribute to ongoing skepticism regarding the company’s operational health and market positioning.
Consensus Ratings
The recent upgrade from Raymond James reflects a more favorable outlook among analysts, albeit within a mixed consensus. Currently, TFX has a balance of six ratings: three “Buys,” three “Holds,” and no “Sells.” The average price target set by analysts stands at roughly $130.67, with a high target of $147 and a low of $116. This range indicates that while there is room for growth, analysts remain divided, reflecting the ongoing uncertainty surrounding TFX. The latest rating upgrade reinforces optimism, but investors should consider potential risks given the mixed signals from the overall analyst consensus.
Stock Grading / Fundamental View
Teleflex holds a Stocks Telegraph Grade score of 32, indicating underlying challenges but also potential for recovery. This score reflects the company’s overall health and investment profile, suggesting that while TFX may be facing difficulties now, there remains the possibility for improvement. Investors should consider this score alongside market sentiment and fundamental performance metrics when evaluating potential investment in the company’s shares.
Conclusion
Teleflex presents a unique case for investors: the recent upgrade and implied upside set against a backdrop of poor historical performance and alarming earnings results. While the current rating offers a glimmer of optimism for long-term growth investors, potential purchasers must weigh the company’s substantial risks. The upgrade from Raymond James may attract more speculative interest, yet the significant earnings miss hints at deeper operational challenges that investors should monitor closely. Overall, TFX may appeal to those looking for recovery plays within the healthcare sector, albeit with cautious consideration of the inherent risks involved. As the stock navigates these turbulent waters, it remains a compelling watch for discerning investors and analysts alike.